Biohaven Pharmaceuticals, Inc: Commercial-stage biopharmaceutical company with programs including CGRP receptor antagonist, glutamate modulation, and myeloperoxidase inhibition platofrms. NURTECĀ® ODT, a CGRP receptor antagonist, was approved in 1Q20 for acute treatment of migraine. Topline results expected 1Q20 for Ph 3 study of rimegepant in migraine prevention. In glutamate modulation, topline results expected 2Q20 in Ph 2/3 study of troriluzole in OCD. Ph 2/3 study of troriluzole in Alzheimer's is ongoing, with successful futility analysis in Dec 2019. Ph 3 study of troriluzole in SCA is ongoing. In myeloperoxidase inhibition, Ph 3 study of verdiperstat for MSA is ongoing.

$316.7M in cash at the end of 2019, and $282.3M raised in 1Q20 to support NURTEC ODT launch.
Based in...
US - New England
Clinical Stage
Phase III
Disease Space
Central Nervous System, Rare Disease
Public, USA
Market Cap
1B +
Therapeutic Modalities
Small Molecule
215 Church Street
New Haven, CT 06510
United States

Company Participants at Solebury Trout Management Access SF 2020

  • Charles Conway, Chief Scientific OFficer
  • Clifford Bechtold, Chief Operating Officer
  • Jim Engelhart
  • Vlad Coric, M.D., Chief Executive Officer

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Biohaven Pharmaceutical Holding Company Ltd.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Capital Research & Management Co. (International Investors) 11.66 6,003,735 429.78 13F 2020-03-31
Capital Research & Management Co. (Global Investors) 10.56 5,438,070 389.28 Funds 2020-03-31
Wellington Management Co. LLP 6.05 3,118,373 223.23 13F 2020-03-31
1919 Investment Counsel LLC 5.51 2,838,438 203.19 13F 2020-03-31
Marshall Wace LLP 4.98 2,563,443 183.50 13F 2020-03-31
Capital Research & Management Co. (World Investors) 4.27 2,197,854 157.33 13F 2020-03-31
RP Management LLC 4.10 2,111,111 151.12 13F 2020-03-31
State Street Corp. 3.84 1,975,941 141.45 13F 2020-03-31
Oracle Investment Management, Inc. 3.63 1,870,743 133.92 13F 2020-03-31
Eventide Asset Management LLC 3.46 1,783,761 127.69 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.